A traditional Chinese medicine composition, a preparation method therefor and application thereof

Abstract

The application belongs to the technical field of traditional Chinese medicine preparation, and discloses a traditional Chinese medicine composition, a preparation method and application thereof. One of the traditional Chinese medicine compositions comprises the following raw materials in parts by weight: Cyclobalanopsis glauca 50-80 parts, tartary buckwheat 30-50 parts, polygonatum 30-50 parts, honeysuckle 30-50 parts, Poria cocos 10-20 parts, gordon euryale seed 10-20 parts, lotus seed 10-20 parts, medlar 10-20 parts, angelica 10-20 parts, yam 5-15 parts, hawthorn 5-15 parts, and sour jujube seed 5-15 parts. The compound preparation has a good blood glucose-lowering effect, can correct the lipid metabolism disorder of diabetic rats, and reduce liver function damage, has a certain protective effect on the liver, and can be applied to the preparation of a medicine for treating non-alcoholic fatty liver. On this basis, in addition to adding part of the medicinal materials, the traditional Chinese medicine composition can also be applied to the preparation of a medicine for treating chronic obstructive pulmonary disease and a medicine for treating bacterial pneumonia.

Description

TECHNICAL FIELD

[0001] The present application belongs to the technical field of traditional Chinese medicine preparation, more particularly to a traditional Chinese medicine composition, a preparation method thereof and an application thereof. BACKGROUND

[0002] Hyperglycemia is an increase in the glucose content in the blood, caused by abnormal glucose metabolism regulation due to a lack of insulin, mainly manifested as polydipsia, polyphagia, polyuria and weight loss, etc. The normal value of fasting blood glucose is below 6.1 mmol / L, and the normal value of postprandial blood glucose is below 7.8 mmol / L. If it is higher than this range, it is called hyperglycemia. Hyperlipidemia refers to a high blood lipid level, which directly causes some serious diseases harmful to human health, such as coronary heart disease, pancreatitis and atherosclerosis. Hyperlipidemia is divided into primary and secondary types. The primary type is caused by environmental factors, and the secondary type often occurs in metabolic disorder diseases or is related to age factors. The severe type can also cause diabetes, that is, a series of metabolic disorder syndromes caused by a variety of pathogenic factors acting on the body, leading to decreased function of islets of Langerhans and inability of insulin to play a corresponding regulatory role.

[0003] At present, western medicines for treating hyperglycemia mainly involve the following types: metformin, insulin, sulfonylureas and alpha-glucosidase inhibitors. However, these drugs have obvious toxic and side effects when reducing blood glucose, such as damage to liver and kidney functions, digestive tract reactions, skin allergies, etc. Traditional Chinese medicines are widely used due to their small side effects, small gastrointestinal irritation, no damage to liver and kidney, etc. Hyperglycemia and hyperlipidemia are chronic diseases, and single traditional Chinese medicine cannot achieve the effect of treating symptoms and root causes. The compatibility of traditional Chinese medicines is the main feature of traditional Chinese medicine, and occupies a very important position in the cognition of traditional Chinese medicine. The traditional Chinese medicine compound prepared therefrom can be treated from all directions, multiple angles and multiple targets, and has incomparable advantages over single traditional Chinese medicine. However, the existing traditional Chinese medicine formula has limitations. Most of them simply use the traditional decoction method or the simple crushing method to prepare various dosage forms. The dosage of medicinal materials is large, the dosage is unknown, the effect of reducing blood glucose and blood lipids is poor, and there is a potential safety hazard as a long-term preventive drug.

[0004] Chronic obstructive pulmonary disease, simply referred to as chronic obstructive pulmonary disease (COPD), is a kind of lung disease with airflow limitation, which is not completely reversible and develops progressively. Its etiology is usually considered to be related to abnormal inflammatory response of the lung to harmful gases or harmful particles, including chronic bronchitis, bronchial asthma and chronic obstructive emphysema. The clinical manifestations are mainly cough, sputum, wheezing, wheezing in the throat, chest tightness and fullness. At present, the traditional Chinese medicine formula for treating chronic obstructive pulmonary disease only treats symptoms and has no effect on the root cause, and its effect is poor and has certain toxic and side effects.

[0005] Pneumonia refers to the infectious inflammation of alveoli, distal airway and pulmonary interstitium. Among them, bacterial pneumonia is the most common pneumonia and one of the most common infectious diseases. Due to the wide use of broad-spectrum antibiotics, the drug resistance of Klebsiella pneumoniae increases year by year, and the drug resistance of the bacteria is multiple and extensive, so that the treatment becomes extremely difficult, greatly increasing the mortality of patients.

[0006] Therefore, how to provide a traditional Chinese medicine composition with obvious effect, no toxic side effect, and capable of treating non-alcoholic fatty liver, chronic obstructive pulmonary disease and bacterial pneumonia is a problem to be solved by those skilled in the art. SUMMARY

[0007] In order to overcome the defects and deficiencies in the prior art, the present application provides a traditional Chinese medicine composition, a preparation method and application thereof, which has good blood glucose and blood lipid lowering effect, no toxic side effect, and reasonable compatibility. On this basis, in addition to the addition of part of medicinal materials, it can also be applied to the preparation of drugs for treating chronic obstructive pulmonary disease and bacterial pneumonia.

[0008] In order to achieve the above-mentioned purpose, the present application adopts the following technical solutions:

[0009] One of the purposes of the present application is to provide a traditional Chinese medicine composition, which comprises the following raw materials by weight: Cyclobalanopsis glauca 50-80 parts, tartary buckwheat 30-50 parts, polygonatum 30-50 parts, honeysuckle 30-50 parts, Poria cocos 10-20 parts, gordon euryale seed 10-20 parts, lotus seed 10-20 parts, medlar 10-20 parts, angelica 10-20 parts, yam 5-15 parts, hawthorn 5-15 parts, and sour jujube kernel 5-15 parts.

[0010] The preparation method of the above-mentioned traditional Chinese medicine composition comprises the following steps:

[0011] (1) The Cyclobalanopsis glauca, tartary buckwheat, polygonatum and honeysuckle are compounded according to the weight ratio, frozen and ultra-finely pulverized, added into deionized water and added with a composite enzyme for ultrasonic-assisted enzyme extraction, then centrifuged to extract the supernatant;

[0012] (2) The remaining raw materials are compounded according to the weight ratio, frozen and ultra-finely pulverized, and added with 60-80% ethanol for extraction to obtain an extraction solution;

[0013] (3) The supernatant and the extraction solution are combined, adsorbed with a macroporous adsorption resin, eluted with deionized water first and then with 60%-80% ethanol to obtain an eluate;

[0014] (4) The eluate is passed through a nanofiltration membrane, then concentrated under reduced pressure to obtain an extract, and freeze-dried to obtain the product.

[0015] Preferably, the composite enzyme in step (1) is cellulase, pectinase and protease, and the mass ratio is 7-10:2-5:1-3.

[0016] Preferably, in step (1), the ultrasonic-assisted enzymatic extraction is controlled at a material-liquid ratio of 1:10-20 g / mL, an ultrasonic power of 500-800 W, and an extraction temperature of 60-90 DEG C for 15-30 min.

[0017] Preferably, in step (2), the extraction is controlled at a material-liquid ratio of 1:8-15 g / mL and an extraction temperature of 60-80 DEG C for 30-60 min.

[0018] Preferably, in step (3), the HP-20 macroporous adsorption resin is used, the column diameter to height ratio is 1:8-10, and the elution volume of ethanol is 5-30 times the volume of the macroporous adsorption resin.

[0019] Preferably, in step (4), the nanofiltration membrane has a molecular weight cut-off of 50-150 Da.

[0020] Preferably, in step (4), the concentration is performed under reduced pressure to a relative density of 1.0-1.4.

[0021] The above-mentioned Chinese medicinal composition is used for preparing a drug for treating non-alcoholic fatty liver.

[0022] The second object of the present application provides a Chinese medicinal composition for treating non-alcoholic fatty liver, which comprises the following raw materials in parts by weight: Cyclocarya 50-80 parts, tartary buckwheat 30-50 parts, polygonatum 30-50 parts, honeysuckle 30-50 parts, Poria cocos 10-20 parts, gordon euryale seed 10-20 parts, lotus seed 10-20 parts, medlar 10-20 parts, angelica 10-20 parts, yam 5-15 parts, hawthorn 5-15 parts, semen ziziphi spinosae 5-15 parts, pueraria 15-30 parts, polygonatum odoratum 15-30 parts, lily 15-30 parts, citrus aurantium 5-15 parts, Terminalia chebula 5-15 parts, rhodiola 5-15 parts, and ginkgo 5-15 parts.

[0023] The above-mentioned Chinese medicinal composition is used for preparing a drug for treating chronic obstructive pulmonary disease.

[0024] The third object of the present application provides a Chinese medicinal composition for treating chronic obstructive pulmonary disease, which comprises the following raw materials in parts by weight: Cyclocarya 50-80 parts, tartary buckwheat 30-50 parts, polygonatum 30-50 parts, honeysuckle 30-50 parts, Poria cocos 10-20 parts, gordon euryale seed 10-20 parts, lotus seed 10-20 parts, medlar 10-20 parts, angelica 10-20 parts, yam 5-15 parts, hawthorn 5-15 parts, semen ziziphi spinosae 5-15 parts, platycodon 10-30 parts, bergamot 10-30 parts, ophiopogon 10-30 parts, loquat leaf 10-30 parts, fritillaria 10-20 parts, centella asiatica 10-20 parts, and biota leaf 10-20 parts.

[0025] The above-mentioned Chinese medicinal composition is used for preparing a drug for treating bacterial pneumonia.

[0026] The pharmacological effects of the raw materials of the present application are as follows:

[0027] Cyclobalanopsis glauca: has various natural ingredients for reducing blood sugar, effectively increases enzyme activity in the liver, can reduce and accelerate the decomposition and utilization of glucose, reduces the output of liver glycogen, improves the resistance of islets, regulates glucose metabolism, and also has the effects of clearing heat and moistening dryness.

[0028] Tartary buckwheat: bitter in taste, flat and cold in nature, has the effects of benefiting qi, continuing spirit, benefiting ears and eyes, and has the effects of reducing qi and invigorating stomach, clearing heat and removing dampness. Modern research shows that various active ingredients have the effects of relieving "three highs", reducing uric acid, and improving cardiovascular circulation.

[0029] Rhizoma Polygonati: is a plant of Polygonatum of Liliaceae, and pharmacological experiments show that it has the effects of resisting pathogenic microorganisms, resisting fatigue, resisting oxidation, and resisting viruses, and has certain effects on blood sugar control. It can tonify lung yin and moisten the lung to stop coughing.

[0030] Honeysuckle: has the effects of clearing heat and resolving toxins, and dispersing wind-heat. It is cold in nature and is good at resolving toxins in clearing heat, and has the effect of clearing fire and toxin evil. Honeysuckle has the pharmacological effects of broad-spectrum antibacterial, antiviral, heat-clearing, anti-inflammatory, liver-protecting, gallbladder-protecting, blood lipid-lowering, blood sugar-lowering, and hemostatic. Honeysuckle decoction can significantly enhance the body's immunity, and the extract has a reducing effect on experimental hyperglycemia, and the mechanism may be related to the inhibition of intestinal glucosidase activity or the antagonism of free radicals, the protection of pancreas, and cells. In addition, it can also reduce the serum and liver tissue triglyceride levels of hyperlipidemia model animals.

[0031] Poria cocos: has the effects of promoting water excretion and dampness, invigorating the spleen, calming the heart and soothing the nerves.

[0032] Euryale ferox: can tonify the spleen and remove dampness, and can benefit the kidney and astringe essence.

[0033] Lotus seed: clears heat and reduces fire, tonifies the spleen to stop diarrhea, and strengthens the heart and soothes the nerves.

[0034] Medlar: nourishes the liver and kidney, moistens lung yin, and stops coughing.

[0035] Angelica: mainly has the effects of tonifying blood and activating blood.

[0036] Chinese yam: tonifies qi and yin, tonifies the spleen, lung and kidney, and can tonify lung qi and tonify lung yin.

[0037] Hawthorn: promotes blood circulation and removes blood stasis, and transforms turbidity and lowers lipid.

[0038] Semen Ziziphi Spinosae: tonifies the liver and kidney, nourishes blood and yin, and calms the heart and soothes the nerves.

[0039] Radix Puerariae: resolves the muscle and reduces fever, generates saliva and stops thirst, and unblocks the channels and activates the collaterals.

[0040] Polygonatum odoratum: has the effects of nourishing yin and moistening dryness, and generating saliva and stopping thirst.

[0041] Lily: efficacy for nourishing yin and moistening lung, clearing heart and soothing the mind, treating yin deficiency and dry cough, labor cough and hemoptysis.

[0042] Citron: has the effects of soothing liver and regulating qi, regulating the middle, and reducing sputum.

[0043] Chebulic myrobalan: has the effects of astringing intestine to stop diarrhea, astringing lung to stop cough, and reducing fire to benefit throat.

[0044] Red sage: enters lung and spleen channels, can benefit qi and invigorate spleen, relieve asthma and stop cough, and is used to treat spleen deficiency, fatigue and weakness.

[0045] Ginkgo nut: contains flavonoids, has the effect of lubrication and moisturizing, can nourish yin and supplement lung, astringe lung and relieve asthma, and relieve cough.

[0046] Cithin: has the effects of promoting lung, benefiting throat, reducing sputum, and draining pus, and is used for cough with much phlegm, chest stuffiness, sore throat and hoarseness, and lung abscess with pus.

[0047] Finger citron: soothes liver and regulates qi, dries dampness and reduces sputum.

[0048] Ophiopogon: has the effects of moistening lung and nourishing yin, benefiting stomach and producing saliva, and clearing heart and relieving distress.

[0049] Zhejiang fritillary: has the effects of clearing heat, reducing sputum, and relieving cough, detoxifying, resolving masses, and resolving abscesses.

[0050] Centella asiatica: has the effects of clearing heat and reducing dampness, detoxifying and detumescing.

[0051] Biota orientalis: has the effects of cooling blood to stop bleeding, reducing sputum to stop cough, and promoting hair growth.

[0052] According to the technical scheme, compared with the prior art, the present application provides a traditional Chinese medicine composition, a preparation method and application thereof, and has the following beneficial effects:

[0053] (1) The present application discloses a traditional Chinese medicine composition and its application in preparing a medicine for treating non-alcoholic fatty liver. Qingqianliu, bitter buckwheat, rhizoma polygonati, honeysuckle are used as main drugs, which can clear heat and detoxify, enhance the body's immunity, and have good hypoglycemic effect; the combined action of fuling, gorgon, lotus seed, medlar, angelica, yam, hawthorn, and sour jujube kernel can benefit water and remove dampness, tonify the spleen and kidney, strengthen the heart and calm the mind, nourish the liver and kidney, tonify blood, and benefit qi and nourish yin, which can improve the body's immunity, enhance the constitution, avoid the harm of cold and cool main drugs to the human body, and benefit the recovery of patients. The components can correct the disturbed lipid metabolism of diabetic rats, reduce liver function damage, have a certain protective effect on the liver, can be applied to prepare a medicine for treating non-alcoholic fatty liver, reduce blood sugar and blood lipids, have no toxic side effects, and avoid the damage caused by traditional Chinese medicine composition.

[0054] (2) The application also discloses a traditional Chinese medicine composition, which is found in practice that can be applied to the preparation of a drug for treating chronic obstructive pulmonary disease. The traditional Chinese medicine composition comprises Qingqianliu, bitter buckwheat, Rhizoma Polygonati, honeysuckle as main drugs, which can clear heat and resolve toxins, resist pathogenic microorganisms, resist fatigue and resist oxidation; Fuling, Gualou, Lianzi, Gouqi, Danggui, Shanyao, Shanzha, Suanzaoren jointly act, can benefit water and remove dampness, tonify the spleen and kidney, strengthen the heart and calm the nerves, nourish the liver and kidney, tonify blood and invigorate blood, benefit qi and nourish yin, can improve human immunity, enhance physical fitness, avoid the harm of cold main drugs to the human body, and is beneficial to patient recovery; in addition, Gegen, Yuzhu, Baihe, Xiangrou, Hezi, Hongjingtian and Baiteng can dredge the channels and collaterals, nourish yin and moisten dryness, expand the middle and resolve phlegm, astringe the lung and stop cough, and clear away heat and benefit the throat. The obtained composition can significantly reduce the IL-4, IL-8 and TNF-α contents in serum, alveolar and lung tissue fluid of chronic obstructive pulmonary disease rats, close to normal level, and has a positive effect on treating chronic obstructive pulmonary disease.

[0055] (3) The application also discloses a traditional Chinese medicine composition, which can be applied to the preparation of a drug for treating bacterial pneumonia. The traditional Chinese medicine composition comprises Qingqianliu, bitter buckwheat, Rhizoma Polygonati, honeysuckle as main drugs, which can clear heat and resolve toxins, resist pathogenic microorganisms, resist fatigue and resist oxidation; Fuling, Gualou, Lianzi, Gouqi, Danggui, Shanyao, Shanzha, Suanzaoren jointly act, can benefit water and remove dampness, tonify the spleen and kidney, strengthen the heart and calm the nerves, nourish the liver and kidney, tonify blood and invigorate blood, benefit qi and nourish yin, can improve human immunity, enhance physical fitness, avoid the harm of cold main drugs to the human body, and is beneficial to patient recovery; in addition, Jiegeng, Foshou, Maidong, Pipa leaf, Zhebeimu, Jixuecao and Caibaiye have the effects of promoting lung and benefiting throat, drying dampness and resolving phlegm, moistening lung and nourishing yin, clearing away heat and dampness, and detoxifying and detumescing. The lung index of rats treated by the composition is obviously reduced, and TNF-α and IL-6 are significantly reduced, which has a certain therapeutic effect on bacterial pneumonia rats.

[0056] (4) The freeze ultrafine grinding of the application can make part of materials achieve the effect of breaking the wall, which is more beneficial to human body absorption. Meanwhile, the friction heat generated in the grinding process is reduced or lowered. The effective components of the materials are protected, so as to reduce the loss of effective components. The ultrasonic auxiliary complex enzyme hydrolysis structure of the dense plant cell wall can promote the plant cell tissue to break the wall or deform, which is beneficial to the dissolution of intracellular total saponins, flavonoids and other active substances. Meanwhile, a large amount of insoluble substances such as starch and protein in the residue can be hydrolyzed, which can avoid the loss of active substances, increase the extraction rate, and reduce the transfer time of active components from plant materials to solvent, so that the extraction time is short. DETAILED DESCRIPTION

[0057] The technical solutions in the embodiments of the application will be described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the application, rather than all the embodiments. Based on the embodiments in the application, all other embodiments obtained by those skilled in the art without creative work belong to the protection scope of the application.

[0058] Embodiment 1

[0059] A traditional Chinese medicine composition, comprising the following raw materials by weight: Cyclobalanopsis glauca 80 parts, tartary buckwheat 50 parts, polygonatum 50 parts, honeysuckle 50 parts, Poria cocos 15 parts, Gorgon 15 parts, lotus seed 15 parts, medlar 15 parts, angelica 15 parts, yam 10 parts, hawthorn 10 parts, and sour jujube kernel 10 parts.

[0060] The preparation method of the traditional Chinese medicine composition, characterized by comprising the following steps:

[0061] (1) The Cyclobalanopsis glauca, tartary buckwheat, polygonatum, and honeysuckle are compounded according to the weight ratio, and are subjected to frozen ultrafine grinding, and are put into deionized water and added with a composite enzyme, and are subjected to ultrasonic-assisted enzyme extraction, and then are centrifuged to extract the supernatant;

[0062] (2) The remaining raw materials are compounded according to the weight ratio, and are subjected to frozen ultrafine grinding, and are added with 60-80% ethanol for extraction to obtain an extraction liquid;

[0063] (3) The supernatant and the extraction liquid are combined, and are adsorbed by a macroporous adsorption resin, and then are eluted with deionized water first and then with 80% ethanol to obtain an eluate;

[0064] (4) The eluate is passed through a nanofiltration membrane, and is then concentrated under reduced pressure to obtain an extract, and is freeze-dried to obtain the product.

[0065] The composite enzyme in step (1) is cellulase, pectinase, and protease, and the mass ratio is 10:5:3.

[0066] The ultrasonic-assisted enzyme extraction in step (1) controls the solid-liquid ratio to be 1:20 g / mL, and the ultrasonic power is 800 W, and the extraction is carried out at 90°C for 30 min.

[0067] The extraction in step (2) controls the solid-liquid ratio to be 1:15 g / mL, and the extraction is carried out at 80°C for 60 min.

[0068] In step (3), the HP-20 type macroporous adsorption resin is used, the column diameter to height ratio is 1:10, and the elution volume of ethanol is 20 times the volume of the macroporous adsorption resin.

[0069] The nanofiltration membrane in step (4) has a molecular weight cut-off of 50-150 Da.

[0070] In step (4), the concentration under reduced pressure is carried out to a relative density of 1.4.

[0071] Embodiment 2

[0072] A traditional Chinese medicine composition, comprising the following raw materials by weight: Cyclobalanopsis glauca 80 parts, tartary buckwheat 50 parts, polygonatum 50 parts, honeysuckle 50 parts, Poria cocos 15 parts, Gorgon 15 parts, lotus seed 15 parts, medlar 15 parts, angelica 15 parts, yam 10 parts, hawthorn 10 parts, Chinese date kernel 10 parts, radix puerariae 30 parts, polygonatum 30 parts, lily 30 parts, citrus medica 15 parts, Terminalia chebula 15 parts, red ginseng 15 parts, white ginkgo 15 parts.

[0073] The preparation method of the traditional Chinese medicine composition, characterized by comprising the following steps:

[0074] (1) The Cyclobalanopsis glauca, tartary buckwheat, polygonatum, and honeysuckle are compounded according to the weight ratio, and are subjected to frozen ultrafine grinding, and are put into deionized water and added with a composite enzyme, and are subjected to ultrasonic-assisted enzyme extraction, and then are centrifuged to extract the supernatant;

[0075] (2) The remaining raw materials are compounded according to the weight ratio, and are subjected to frozen ultrafine grinding, and are added with 60-80% ethanol for extraction to obtain an extraction solution;

[0076] (3) The supernatant and the extraction solution are combined, and are adsorbed by a macroporous adsorption resin, and then are eluted with deionized water first and then with 80% ethanol to obtain an eluate;

[0077] (4) The eluate is passed through a nanofiltration membrane, and then is concentrated under reduced pressure to obtain an extract, and is freeze-dried to obtain the traditional Chinese medicine composition.

[0078] The composite enzyme in step (1) is cellulase, pectinase, and protease, and the mass ratio is 10:5:3.

[0079] The ultrasonic-assisted enzyme extraction in step (1) controls the solid-liquid ratio to be 1:20 g / mL, and the ultrasonic power is 800 W, and the extraction is carried out at 90°C for 30 min.

[0080] The extraction in step (2) controls the solid-liquid ratio to be 1:15 g / mL, and the extraction is carried out at 80°C for 60 min.

[0081] In step (3), the HP-20 type macroporous adsorption resin is used, the column diameter to height ratio is 1:10, and the elution volume of ethanol is 20 times the volume of the macroporous adsorption resin.

[0082] The nanofiltration membrane in step (4) has a molecular weight cut-off of 50-150 Da.

[0083] In step (4), the concentration under reduced pressure is carried out to a relative density of 1.4.

[0084] Example 3

[0085] Provided is a traditional Chinese medicine composition, comprising the following raw materials in parts by weight: 80 parts of Cyclocarya paliurus, 50 parts of Tartary Buckwheat, 50 parts of Polygonatum sibiricum, 50 parts of Honeysuckle, 15 parts of Poria cocos, 15 parts of Euryale ferox, 15 parts of Lotus seeds, 15 parts of Lycium barbarum, 15 parts of Angelica sinensis, 15 parts of Dioscorea batatas, 10 parts of Crataegus pinnatifida, 10 parts of Ziziphus jujuba seeds, 30 parts of Platycodon grandiflorus, 30 parts of Citron, 30 parts of Radix Ophiopogonis, 30 parts of Loquat leaves, 15 parts of Fritillaria thunbergii, 15 parts of Centella asiatica, and 15 parts of Platycladus orientalis leaves.

[0086] The method for preparing the above-mentioned Chinese medicine composition is characterized by comprising the following steps:

[0087] (1) Cyclocarya paliurus, Tartary Buckwheat, Polygonatum sibiricum, and Honeysuckle were compounded in parts by weight, subjected to ultrafine grinding by freezing, placed in deionized water, and subjected to ultrasonic-assisted enzyme extraction by adding complex enzyme, followed by centrifugation to extract the supernatant;

[0088] (2) compounding the remaining raw materials by weight, freezing and ultrafine grinding, adding 60-80% ethanol for extraction, and obtaining an extract;

[0089] (3) The supernatant and the extract were combined, adsorbed with a macroporous adsorption resin, and then eluted with deionized water and then with 80% ethanol to obtain an eluate;

[0090] (4) The eluate is passed through a nanofiltration membrane, and then concentrated under reduced pressure to obtain an extract, which is freeze-dried.

[0091] The complex enzyme in step (1) is cellulase, pectinase and protease, with a mass ratio of 10:5:3.

[0092] The ultrasonic-assisted enzyme extraction in step (1) is performed at a material-liquid ratio of 1:20 g / mL, an ultrasonic power of 800 W, and extraction at 90° C. for 30 min.

[0093] The extraction in step (2) was controlled at a solid-liquid ratio of 1:15 g / mL, and the extraction was performed at 80° C. for 60 min.

[0094] In step (3), HP-20 macroporous adsorption resin is used, the column diameter-to-height ratio is 1:10, and the ethanol elution volume is 20 times the volume of the macroporous adsorption resin.

[0095] The molecular weight cut-off of the nanofiltration membrane in step (4) is 50-150 Da.

[0096] In step (4), the mixture is concentrated under reduced pressure to a relative density of 1.4.

[0097] Comparative Example 1

[0098] The technical solution of Comparative Example 1 is the same as that of Example 3, except that ultrasound is not performed in step (1).

[0099] Comparative Example 2

[0100] The technical solution of Comparative Example 2 is the same as that of Example 3, except that cellulase is used instead of complex enzyme in step (1).

[0101] The effective substance yield is shown in Table 1:

[0102] Table 1

[0103] Group Example 3 Comparative Example 1 Comparative Example 2 Total saponin yield (%) 15.7 6.9 5.1 Total flavone yield (%) 8.2 3.5 2.6

[0104] Effect of the medicinal composition in Example 1 on rats with chronic obstructive pulmonary disease

[0105] 1. Experimental process

[0106] Fifty SPF male SD rats weighing 210±10 g were raised in an environment with good ventilation, 12 h of illumination per day, a relative humidity of 50±5%, and a temperature of 25°C. The rats were adaptively fed for 7 days, and then randomly divided into a normal control group, a model group, a low-dose group, a medium-dose group, and a high-dose group, with 10 rats in each group.

[0107] The rats in each group were placed in a sealed box and smoked with cigarettes (12 mg of tar, 1.0 mg of nicotine, and 14 mg of CO) at a smoke concentration of 5%, 2 times per day, 1 h per time, with an interval of 8 h between the two times, for a total of 60 days. On the 10th day, the 20th day, and the 40th day, the rats in the model group were given intratracheal injection of lipopolysaccharide (200 μg / 200 μL). The rats in the normal control group were placed in a sealed box but not smoked, and the time and interval were the same as those of the other groups. On the 10th day, the 20th day, and the 40th day, the rats in the normal control group were given intratracheal injection of the same amount of normal saline. The rats in the low-dose group, the medium-dose group, and the high-dose group were given gavage treatment with the medicinal composition of Example 2 at a dose of 5 g / kg, 15 g / kg, and 30 g / kg, respectively, 30 min before smoking each day. In addition to the time in the sealed box, the rats in the three groups were raised in the same environment, and the modeling was completed in 10 weeks.

[0108] 2. Results

[0109] 2.1 2.5 mL of cold normal saline was injected into the bronchus and alveoli, and then slowly withdrawn, and the operation was repeated 5 times. The 5 times of lavage fluid was mixed and shaken. 0.5 mL was accurately measured, the remaining liquid was refrigerated at 4°C, and centrifuged at 1000 r / min for 10 min. The supernatant was taken and stored at -80°C. The centrifuged supernatant was taken and used to determine the content of IL-4, IL-8, and TNF-α in the bronchial and alveolar lavage fluid of the rats in each group using an enzyme-linked immunosorbent assay kit.

[0110] 2.2 Anesthetize the rats, and extract 10 mL of abdominal aortic blood from each group of rats, respectively, and store at 4℃ for 40 min, centrifuge at 3000 r / min for 10 min, and absorb the supernatant and store at -80℃. Take the supernatant, and use an enzyme-linked immunosorbent kit to determine the content of IL-4, IL-8 and TNF-α in the serum of each group of rats.

[0111] 2.3 Weigh 100 mg of rat lung tissue, add 2 mL of ice physiological saline, dilute, and use a high-speed homogenizer to prepare tissue homogenate, centrifuge at 3000 r / min for 10 min in a 4℃ refrigerated centrifuge, take the supernatant, and store at -80℃. Absorb the centrifugal supernatant, and use an enzyme-linked immunosorbent kit to determine the content of IL-4, IL-8 and TNF-α in the lung tissue homogenate of each group of rats.

[0112] Table 2 Content of IL-4, IL-8 and TNF-α in the serum of rats (n = 10, ng / ml)

[0113]

[0114] Table 3 Content of IL-4, IL-8 and TNF-α in the alveolar lavage fluid of rats (n = 10, ng / ml)

[0115]

[0116]

[0117] Table 4 Content of IL-4, IL-8 and TNF-α in the lung tissue fluid of rats (n = 10, ng / ml)

[0118]

[0119] It can be analyzed that, compared with the model group, the preparation of the application can significantly reduce the content of IL-4, IL-8 and TNF-α in the serum, alveolar and lung tissue fluid of rats with chronic obstructive pulmonary disease, close to the normal level, and has a positive effect on the treatment of chronic obstructive pulmonary disease.

[0120] Effect of the traditional Chinese medicine composition on rats with bacterial pneumonia in Experiment Two

[0121] 1. Experimental process

[0122] Take 60 SPF SD rats, half male and half female, weighing 210±10 g, and raise them in an environment with good ventilation, 12 h of illumination per day, a relative humidity of 50±5%, and a temperature of 25℃. First, adaptively feed them for 7 days, and then randomly divide them into a normal control group, a model group, an azithromycin group, a low-dose group, a medium-dose group and a high-dose group, 10 rats in each group.

[0123] The rats are anesthetized, the neck tissue is incised in the middle, the upper trachea is exposed, a syringe is punctured into the trachea and the bacterial solution is dropped. In each group except the normal control group, 0.15 mL of Klebsiella pneumoniae solution with a concentration of 2.4×10 8 After 2 hours, the rats are given intragastric administration, the rats in the low-dose group, the medium-dose group and the high-dose group are given the traditional Chinese medicine composition in Example 3 with a dose of 5 g / kg, 15 g / kg and 30 g / kg respectively, the normal control group and the model group are given distilled water under the same conditions, once a day, and the administration is continuously performed for 5 days.

[0124] 2、Results

[0125] The rats are anesthetized, 10 mL of abdominal aortic blood of the rats in each group is extracted, 40 min of cold storage is performed at 4 ℃, 10 min of centrifugation is performed at 3000 r / min, the supernatant is sucked, and the supernatant is stored at-80 ℃, the content of TNF-α and IL-6 in the serum of the rats in each group is determined by using an enzyme-linked immunosorbent kit, as shown in Table 5. The rats are dissected, the lung tissue of the rats is taken out and weighed, and the lung index is calculated, as shown in Table 4. The lung index (%) = wet lung weight (g) / body weight (g) × 100.

[0126] Table 5 Lung index of rats (n=10, %)

[0127]

[0128] Table 6 Content of TNF-α and IL-6 in serum of rats (n=10, pg / mL)

[0129]

[0130] It can be known from the analysis that the lung index of the rats treated by the composition is obviously reduced, and TNF-α and IL-6 are significantly reduced, and the composition has a certain therapeutic effect on bacterial pneumonia rats.

[0131] Effect of traditional Chinese medicine composition on non-alcoholic fatty liver rats in Experiment Three

[0132] 1、Experimental process

[0133] SPF level SD male rats 90, body weight 210 ± 10 g, feeding environment good ventilation, daily 12 h lighting, relative humidity 50 ± 5 %, temperature 25 °C. First adaptive feeding 2 weeks, then randomly take 10 rats as normal control group, given the basic feed feeding, free drinking water. The rest of the rats with high-fat high-sugar feed (35% bran, 30% lard, 20% sucrose, 13% bone meal, 1% yeast and 1% salt) feeding 30 days, after fasting 12 h, fasting intraperitoneal injection of streptozotocin 35 mg / kg induced 2 type diabetes model, 72 h after the tail blood, blood glucose meter blood glucose, fasting blood glucose ≥ 16.7 mmol / L for modeling successful rats. Randomly take 3 rats for liver tissue HE staining, visible liver steatosis. Blood glucose and liver pathological changes meet the above conditions are non-alcoholic fatty liver model.

[0134] Take 50 modeling successful rats, randomly divided into 5 groups, namely model group, pioglitazone group, low dose group, middle dose group, high dose group. Among them, the low dose group, the middle dose group, the high dose group are respectively given 0.5 g / kg, 2 g / kg, 5 g / kg dose of traditional Chinese medicine composition in example 1 gavage treatment; Pioglitazone group is given 10 mg / kg pioglitazone every day; The normal control group and the model group rats are given normal saline gavage under the same conditions every day. After 42 days, all groups of rats were anesthetized with ether, serum was separated, and blood glucose, blood lipid, liver function indexes were determined.

[0135] 2、Results

[0136] The normal control group diet, drinking water, urine volume has no obvious difference, strong aggressiveness, sensitive reaction, normal weight gain. Modeling successful rats showed poor mental state, dull, hunched back and lying, dull yellow and dry hair color and sparse hair, and polyuria, polydipsia, polyphagia.

[0137] Table 7 blood glucose values of rats in each group (n = 10, mmol / L)

[0138]

[0139] Table 8 blood lipid indexes of rats in each group (n = 10, mmol / L)

[0140]

[0141] As shown in Table 7, the FBG of the model group is significantly higher than that of the normal control group, indicating that the combination of long-term high-sugar high-fat feed and streptozotocin can cause partial damage to the islet beta cells of the rats, leading to compensatory secretion disorder of insulin, thereby increasing the FBG value; after treatment with the compound preparation, the blood glucose is significantly decreased. This result suggests that the compound preparation provided in the application has good blood glucose lowering effect, and the effect under high dose is better than that of pioglitazone.

[0142] As shown in Table 8, compared with the normal control group, the total cholesterol TC and triacylglycerol TG of the model group are significantly increased, indicating that long-term high-sugar high-fat feed and streptozotocin cause disorder of lipid metabolism in rats, and after treatment with the compound preparation, the disorder is reduced. The compound preparation provided in the application can correct the disorder of lipid metabolism in rats.

[0143] Table 9: Liver function indicators of rats in each group (n=10, U / L)

[0144]

[0145] Under 100 times of microscope, it can be seen that the hepatocytes of the model group are swollen, there are fat droplet vacuoles of different sizes in the cells, the cell nucleus is marginal, and a small amount of inflammatory cells infiltrate; the fatty degeneration of the pioglitazone group and the medium and high dose groups is significantly reduced, and the inflammatory cells are significantly reduced. Combined with Table 9, it can be seen that the liver function indicators of the model group are abnormal, which is non-alcoholic fatty liver. The compound preparation provided in the application can reduce alanine aminotransferase ALT and aspartate aminotransferase AST, reduce liver function damage, and has a certain protective effect on the liver.

[0146] The embodiments in the specification are described in a progressive manner, and each embodiment focuses on the difference from other embodiments. The same and similar parts of each embodiment can be referred to each other. For the scheme disclosed by the embodiments, since it corresponds to the method disclosed by the embodiments, the description is relatively simple, and the related parts can be referred to the method part.

[0147] The above description of the disclosed embodiments enables a person skilled in the art to implement or use the application. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein can be implemented in other embodiments without departing from the spirit or scope of the application. Therefore, the application will not be limited to these embodiments shown herein, but will conform to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A Chinese medicine composition for treating non-alcoholic fatty liver disease, characterized in that: The invention is prepared from the following raw materials in parts by weight: 50-80 parts of Cyclocarya paliurus, 30-50 parts of Tartary Buckwheat, 30-50 parts of Polygonatum sibiricum, 30-50 parts of Honeysuckle, 10-20 parts of Poria cocos, 10-20 parts of Euryale ferox, 10-20 parts of Lotus seeds, 10-20 parts of Lycium barbarum, 10-20 parts of Chinese Angelica sinensis, 5-15 parts of Chinese yam, 5-15 parts of Hawthorn, and 5-15 parts of Ziziphus jujuba seeds.

2. The method for preparing a Chinese medicine composition according to claim 1, wherein: The following steps are involved: (1) Cyclocarya paliurus, Tartary Buckwheat, Polygonatum sibiricum, and Honeysuckle were compounded in parts by weight, subjected to ultrafine grinding by freezing, placed in deionized water, and subjected to ultrasonic-assisted enzyme extraction by adding complex enzyme, followed by centrifugation to extract the supernatant; (2) compounding the remaining raw materials by weight, freezing and ultrafine grinding, adding 60-80% ethanol for extraction, and obtaining an extract; (3) combining the supernatant and the extract, adsorbing with a macroporous adsorption resin, eluting with deionized water and then with 60%-80% ethanol to obtain an eluate; (4) The eluate is passed through a nanofiltration membrane, and then concentrated under reduced pressure to obtain an extract, which is freeze-dried.

3. The method for preparing a Chinese medicine composition according to claim 2, wherein: The complex enzyme in step (1) is cellulase, pectinase and protease, and the mass ratio is 7-10:2-5:1-3.

4. The method for preparing a Chinese medicine composition according to claim 2, wherein: In the ultrasound-assisted enzyme extraction in step (1), the material-liquid ratio is controlled to be 1:10-20 g / mL, the ultrasonic power is 500-800 W, and the extraction is carried out at 60-90° C. for 15-30 min.

5. The method for preparing a Chinese medicine composition according to claim 2, wherein: The extraction in step (2) is controlled at a material-liquid ratio of 1:8-15 g / mL, and the extraction is carried out at 60-80° C. for 30-60 min.

6. Use of the traditional Chinese medicine composition according to claim 1 in preparing a medicament for treating non-alcoholic fatty liver disease.

7. A Chinese medicine composition for treating chronic obstructive pulmonary disease, characterized in that: The invention is prepared from the following raw materials in parts by weight: 50-80 parts of Cyclocarya paliurus, 30-50 parts of Tartary Buckwheat, 30-50 parts of Polygonatum sibiricum, 30-50 parts of Honeysuckle, 10-20 parts of Poria cocos, 10-20 parts of Euryale ferox, 10-20 parts of Lotus seeds, 10-20 parts of Wolfberry, 10-20 parts of Angelica sinensis, 5-15 parts of Chinese Yam, 5-15 parts of Hawthorn, 5-15 parts of Ziziphus jujuba seeds, 15-30 parts of Pueraria root, 15-30 parts of Polygonatum odoratum, 15-30 parts of Lilium, 5-15 parts of Citron, 5-15 parts of Terminalia chebula, 5-15 parts of Rhodiola rosea and 5-15 parts of Ginkgo biloba.

8. Use of a traditional Chinese medicine composition according to claim 7 in the preparation of a drug for treating chronic obstructive pulmonary disease.

9. A Chinese medicine composition for treating bacterial pneumonia, characterized in that: The invention is prepared from the following raw materials in parts by weight: 50-80 parts of Cyclocarya paliurus, 30-50 parts of Tartary Buckwheat, 30-50 parts of Polygonatum sibiricum, 30-50 parts of Honeysuckle, 10-20 parts of Poria cocos, 10-20 parts of Euryale ferox, 10-20 parts of Lotus seeds, 10-20 parts of Lycium barbarum, 10-20 parts of Angelica sinensis, 5-15 parts of Chinese yam, 5-15 parts of Hawthorn, 5-15 parts of Ziziphus jujuba seeds, 15-30 parts of Platycodon grandiflorum, 15-30 parts of Citron, 15-30 parts of Ophiopogon japonicus, 15-30 parts of Loquat leaves, 10-20 parts of Fritillaria thunbergii, 10-20 parts of Centella asiatica and 10-20 parts of Platycladus orientalis leaves.

10. Use of a traditional Chinese medicine composition according to claim 9 in preparing a medicine for treating bacterial pneumonia.

Images